Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone + Hydroxychloroquine in Metastatic Breast Cancer
NCT00765765Phase 2Terminated
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Feb 2009
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine in breast cancer, sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Tumor Response Rate at 3 years. Started Feb 2009; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00765765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00765765.